Silexion Therapeutics has finally moved its second-generation KRAS silencer into an active human trial, and that clinical step arrives just as the listing and the cash account are both under strain. The Cayman-domiciled, Israel-operated company that came public through the Moringa combination spent two years preparing SIL204 for locally advanced pancreatic cancer and opened the first site at Tel Aviv Sourasky Medical Center after the June quarter closed. The investment debate is no longer whether the science can reach the clinic. It is whether a micro-cap carrying a going-concern warning can fund a multi-country late-stage program before Nasdaq or the treasury forces a reset.
The June quarter shows the cost of that transition. Research spending more than doubled as subcontractors prepared the trial. Half-year operating cash outflow of $7 million consumed most of the year-end cash pile. Shareholders' equity at period end was $44,000, far below the Nasdaq Capital Market equity minimum. Management later described a mid-August registered offering and a sponsor-note conversion as having lifted pro forma equity above that floor. Four days after the quarterly filing, Nasdaq still sent a delisting notice because subsequent losses left the company short again. A mandatory hearings-panel monitor from last autumn blocks staff from granting extra time.
What the market is pricing is almost no residual option value on SIL204 above a shrinking cash pile. The first-generation LODER study left a numerical survival gap that never cleared statistical significance on a tiny KRAS-selected subset. The second-generation molecule now has Israeli and German authorizations, a Catalent clinical-supply campaign, and a dual-route design that tries to hit the primary tumor and occult metastases together. The next several months resolve whether first patients are actually dosed, whether early circulating-tumor-DNA reads look coherent, and whether the hearings panel stays the listing long enough for any of that to matter.